Nivolumab and Ipilimumab in Recurrent or Refractory Cancer of Unknown Primary: a Phase II Trial
Nature communications(2023)
关键词
Cancer of Unknown Primary,Unknown Primary Tumours
AI 理解论文
溯源树
样例
生成溯源树,研究论文发展脉络
Chat Paper
正在生成论文摘要
Nature communications(2023)